Skip to main content
. Author manuscript; available in PMC: 2011 Mar 3.
Published in final edited form as: Cell Cycle. 2010 Mar 3;9(5):901–908. doi: 10.4161/cc.9.5.10840

Figure 3. LMP2A in human Burkitt’s lymphoma.

Figure 3

(A) In EBV-negative human BL, translocation of MYC to an immunoglobulin locus occurs during a germinal center reaction. MYC induces p53 pathway activation, triggering apoptosis. Cells which have inactivated the p53 pathway grow into lymphoma. (B) In EBV-positive human BL, LMP2A is present during the germinal center reaction and MYC translocation. LMP2A enhances the survival of cells with de-regulated MYC early in lymphomagenesis, allowing expansion of cells that overexpress MYC. The expansion of cells containing deregulated MYC increases the probability of acquisition of a secondary mutation, which leads to tumor progression. After tumor progression, immune regulation selects against high levels of LMP2A in tumor cells, resulting in low levels of LMP2A in tumor biopsies. LMP2A is indicated by the multi spanning transmembrane protein. Constitutive MYC expression either by translocation or transgene construct is indicated by black/grey line in nucleus.

*Figure 2 and Figure 3 are adapted from ref 94.